Targeting of PCSK9 with siRNA for LDL-C Reduction in a High-Risk Population

Target Audience
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, with an interest in developing a core competency in the diagnosis and treatment of dyslipidemia and management of ASCVD and cardiovascular risk.

Program Overview
Heart disease is the leading cause of death for both men and women in the United States, with 610,000 people dying of this disease every year – or 1 in every 4 deaths. Elevated LDL-C is a major risk factor for heart disease. Although there have been consistent educational efforts that focus on lowering LDL-C levels, and the use of statins has progressively increased, there remain significant gaps in overall lipid control. Risk for cardiovascular events persists in patients who may be receiving optimal/maximally tolerated statin treatment. In light of emerging therapies and upcoming cardiovascular outcomes trials (CVOTs), these patients may be able to further reduce their risk in primary and secondary prevention with the appropriate use of non-statin therapies. In order to bring further insight to this evolving landscape of cardiovascular risk management, the NLA presented a supplementary 75-minute symposium during the European Society of Cardiology 2019 Annual Congress on August 31 in Paris, France. Watch the proceedings and claim your credit today!

Learning Objectives
Upon completion of this activity, participants should be able to:

-Explain the role of non-statin therapies in cardiovascular risk management
-Identify proposed methods to improve patient outcomes through overcoming poor adherence and other management barriers
-Assess the implications of ongoing clinical trials for the management of cardiovascular risk
-Summarize the mechanism of action, efficacy, and safety of novel agents for LDL-C and ASCVD risk reduction